Analytik Jena AG Reports Success at Key Industry Trade Fair in France

09.04.2015 | 뉴스

PlasmaQuant® MS Mass Spectrometer One of the Top Three Nominations for the Innovation Award

Paris/Jena, April 9, 2015 — At this year’s Forum LABO & BIOTECH, the most important industry trade fair for analytics, laboratory technology, and biotechnology, Analytik Jena AG’s new PlasmaQuant® MS mass spectrometer was one of the top three nominations for the trade fair’s Innovation Award in the category Productivity and Profitability. With this award, Forum LABO & BIOTECH recognizes product innovations in which particular emphasis was placed on ease of use during development.

“I’m delighted with this nomination. It’s a testament to all of our work,” says Michel Alric, Managing Director of the French Group company Analytik Jena France S.A.R.L. Just half a year after the acquisition of the Bruker Corporation’s ICP-MS segment, Analytik Jena AG launched two new products for mass spectrometry with inductively coupled plasma (ICP-MS technology) in February: PlasmaQuant® MS and PlasmaQuant® MS Elite. The market launch in France was kicked off at Forum LABO & BIOTECH last week.

Alric was also extremely satisfied with the trade fair as a whole. “The week proved to be very successful. The atmosphere was exceptional, the discussions good, and the market launch of PlasmaQuant® MS went very well. Forum LABO is a key success factor for Analytik Jena in France. We are still in the process of finding our feet in this market and see plenty of potential for orders,” explains Alric.

Analytik Jena has been represented in France by its own subsidiary since 2013. Just this spring, it opened a new application laboratory in Saint-Auban on the outskirts of Paris.

Print-quality photos for the press release are available for download at http://www.analytik-jena.de/en/company/press/downloads/photos-for-press-releases.html


Contact

Contact the press officer
PR & Media+49 3641 77 7357presse@analytik-jena.com

Contact us

The newsletter of Analytik Jena frequently keeps you posted about:

Sign up here